

[Home](#) [Sitemap](#) [Contact Us](#)search [About Elan](#) [Products](#) [Drug Delivery](#) [Your Health](#) [Research](#) [Investor Relations](#) [Careers](#)
1999 2000 2001 **2002****01/18/2002**

For more information contact:

Investors (U.S.):Jack Howarth
Ph: 212-407-5740
800-252-3526**Investors (Europe):**Emer Reynolds
Ph: 353-1-709-4000
00800 28352600**Media:**Max Gershenoff
Ph: 212-407-5740
800-252-3526**Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792**

Dublin, Ireland/ Madison, New Jersey, January 17, 2002 -- Elan Corporation, plc (NYSE: ELN) ('Elan') and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation (NYSE: AHP) ('AHP'), today reported on developments in the Phase 2A clinical trial of AN-1792, an experimental immunotherapeutic for the treatment of mild to moderate Alzheimer's disease.

The companies have decided to temporarily suspend dosing in this Phase 2A study after four patients in France were reported to have clinical signs consistent with inflammation in the central nervous system. All four patients are receiving appropriate medical care and the companies are working with clinical investigators to determine the cause of this development.

Elan and AHP are conducting clinical trials in the US and four European countries in patients with Alzheimer's disease using AN-1792 (also known as AIP-001). To date, approximately 360 patients have received multiple doses of AN-1792. In the Phase 2A study, 97 patients in France have received study drug. The four reported cases of central nervous system inflammation were in patients receiving AN-1792.

There are many agents and mechanisms that can result in inflammation of the central nervous system, one being a viral infection. The presence of virus within the cerebrospinal fluid was reported in some of the four patients under investigation. However, the cause of the inflammation remains to be determined. Elan and AHP will provide further guidance regarding the resumption of dosing following the thorough investigation and consultation with an independent safety monitoring committee,

study physicians and regulatory authorities. It is important to note that the study is still ongoing and that the dosing schedule should provide time for the clinical investigation to occur without jeopardizing study conduct.

"The well-being of patients is always our paramount concern. Our decision to temporarily suspend further dosing, pending the results of our evaluation, is a standard approach to protect the safety of patients in clinical trials," stated Dr. Ivan Lieberburg, Elan's Chief Scientific and Medical Officer. "A decision will be made on resumption of dosing pending the outcome of this investigation."

Elan and AHP announced in July 2001 the intention to further study AN-1792 in the clinic. This compound represents the first in a series of therapeutic agents currently under development within this collaboration.

In Phase 1 safety studies, AN-1792 was administered to more than 80 patients with mild to moderate Alzheimer's disease in a variety of dosage regimens. The results from the U.S. single dose trial and the U.K. multiple dose trial indicated that AN-1792 was well tolerated and that a proportion of patients developed an appropriate immunological response to AN-1792.

The Phase 2A study was designed to measure the immune response to beta amyloid peptide immunization in patients with Alzheimer's disease. Patients with mild to moderate Alzheimer's disease were enrolled and evaluated using conventional cognitive tests and by other surrogate measures. The results of this study are expected to provide additional information regarding the immune response to AN-1792, as well as valuable information useful for the development of other therapeutic agents being studied as part of the collaborative development program.

Elan Corporation, plc is a leading worldwide, fully integrated biopharmaceutical company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and the United Kingdom. Elan is focused on the marketing of therapeutic products and services in neurology, pain management, oncology, infectious disease and dermatology and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. Elan shares trade on the New York, London and Dublin Stock Exchanges.

Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular therapies, central nervous system drugs, anti-inflammatory agents, infectious disease, hemophilia, oncology, vaccines, and generic pharmaceuticals. American Home Products is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs

and over-the-counter medications. It also is a leader vaccines, biotechnology and animal health care.

The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the clinical development of AN-1792 and whether it will ever be approved for commercialization. Factors which could cause actual results to differ materially from the companies' current expectations include the risk that problems or delays may arise during preparations for clinical trials or in the course of development, testing or manufacturing of the product, that results in later stage or larger trials may be different than those safety profile in subsequent trials or may not meet applicable regulatory standards as well as the other risks and uncertainties described from time to time in the companies' periodic reports filed with the Security and Exchange Commission.

Other contact
details:

Investors

AHP	Justin Victoria	Ph: +1 943 660 5340
-----	--------------------	---------------------

Media

AHP	Lowell Weiner	Ph: +1 973 660 5013 weinerl@ahp.com
-----	------------------	--

Wyeth Ayers	Douglas Petkus	Ph: +1 610 902 7336 petkusd@labs.wyeth.com
-------------	-------------------	---

[Back](#)



Copyright © 2001 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | [Privacy Policy](#) | [Terms of use](#)

[Home](#) [Sitemap](#) [Contact Us](#)search [About Elan](#) [Products](#) [Drug Delivery](#) [Your Health](#) [Research](#) [Investor Relations](#) [Careers](#)
1999 2000 2001 **2002****03/01/2002**

For more information contact:

Investors (U.S.):Jack Howarth
Ph: 212-407-5740
800-252-3526**Investors (Europe):**Emer Reynolds
Ph: 353-1-709-4000
00800 28352600**Media:**Max Gershenoff
Ph: 212-407-5740
800-252-3526**Elan and Wyeth provide update on status of Alzheimer's collaboration**

Dublin, Ireland/ Madison, New Jersey, March 1, 2002 -- Elan Corporation, plc (NYSE: ELN) ("Elan") and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation (NYSE: AHP) ("AHP"), announced today they have decided not to resume further dosing of AN-1792, an experimental immunotherapeutic under development for the treatment of mild to moderate Alzheimer's disease.

In early January, Wyeth and Elan suspended all clinical dosing with AN-1792 in the exploratory Phase 2A study immediately after learning that four patients in France were reported to have experienced clinical signs consistent with inflammation in the central nervous system ("CNS"). Since the companies halted dosing in January, eleven additional patients were reported with symptoms associated with CNS inflammation.

The companies, in consultation with the independent Safety Monitoring Committee, have concluded that no additional patients shall be treated with AN-1792, but patients will continue to be followed to assess on-going safety. The companies are continuing their pre-clinical and clinical investigations into these cases and are in regular contact with regulatory agencies in the US and Europe regarding the progress of this effort.

All patients who experienced this event have, or are, receiving medical care and most have shown improvement or recovered. The companies are aggressively collaborating with clinical investigators to better understand the cause of this phenomenon. Information regarding these events will be communicated to patients or their caregivers on an ongoing basis.

"We will continue to monitor all patients who have received drug in these studies," says Dr. Ivan Lieberburg, Elan's Chief Scientific and Medical Officer. "The well-being of patients is always our paramount concern. Our decision to first suspend dosing, and now permanently discontinue dosing in this exploratory phase of clinical research with this single compound, in our opinion, remains in the best interest of the health and safety of patients. There are additional compounds under preclinical evaluation as part of this collaboration. We believe that these alternative therapeutic candidates may result in a treatment for Alzheimer's disease."

AHP and Elan have formed one of the broadest research alliances in the pharmaceutical industry to develop immunotherapeutic approaches to treat and prevent Alzheimer's disease. AN-1792 represents the first in a series of therapeutic approaches currently under development within this collaboration that explore the clinical potential of immunotherapy for Alzheimer's disease. Elan and Wyeth are committed to further research and to finding a cure for Alzheimer's disease, an affliction that claims millions of lives each year.

"These developments are not uncommon in early clinical research with an innovative compound like AN-1792," says L. Patrick Gage, President, Wyeth-Ayerst Research. "Our immediate goals are two-fold – the safety of all patients involved in these trials; and to gain a greater understanding of the nature of these events. Both companies are committed to developing a treatment for Alzheimer's disease and we are hopeful that our alternative Alzheimer's approaches will continue to advance in development."

Clinical trials with AN-1792 were being conducted in the US and four European countries in patients with Alzheimer's disease using AN-1792 (also known as AIP-001). Approximately 360 patients had received multiple doses of AN-1792. The Phase 2A study was designed to measure the immune response to immunisation with the study drug, as well as changes in other parameters in Alzheimer's patients with mild to moderate disease. Patients were enrolled and evaluated by conventional cognitive tests and by other surrogate measures. The results of this study were expected to provide additional information regarding the immune response to AN-1792, as well as valuable information useful for the design and evaluation of other therapeutic agents being studied in the collaborative development program.

Alzheimer's disease is the most common cause of dementia; and the fourth leading cause of death in developed countries. It is a major health problem worldwide, and has an enormous impact on individuals, families, the health care system, and society as a whole. It is estimated that more than four million people in the U.S. currently have Alzheimer's disease, and its prevalence doubles every five years beyond age 65.

Elan Corporation, plc is a leading worldwide, fully integrated biopharmaceutical company headquartered in Ireland, with its

principal research, development, manufacturing and marketing facilities located in Ireland and the United States. Elan is focused on the marketing of therapeutic products and services in neurology, pain management, oncology, infectious disease and dermatology and on the development and commercialisation of products using its extensive range of proprietary drug delivery technologies. Elan shares trade on the New York, London and Dublin Stock Exchanges.

Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular therapies, central nervous system drugs, anti-inflammatory agents, infectious disease, haemophilia, oncology, vaccines, and generic pharmaceuticals. American Home Products is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. It also is a leader vaccines, biotechnology and animal health care.

The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the clinical development of AN-1792 and whether it will ever be approved for commercialisation. Factors which could cause actual results to differ materially from the companies' current expectations include the risk that problems or delays may arise during preparations for clinical trials or in the course of development, testing or manufacturing of the product, that results in later stage or larger trials may be different than those safety profile in subsequent trials or may not meet applicable regulatory standards as well as the other risks and uncertainties described from time to time in the companies' periodic reports filed with the Security and Exchange Commission.

Investors Contact:

American Home Products

Justin Victoria | Ph: 973-660-5340

Media Contact

American Home Products

Lowell Weiner | Ph: 973-660-5013 | weinerl@ahp.com

Wyeth-Ayerst

Douglas Petkus | Ph: 610-902-7336 | petkusd@labs.wyeth.com

Back



Copyright © 2001 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | [Privacy Policy](#) | [Terms of use](#)